This observational long-term follow-up study monitors people who received vMCO-I by intravitreal injection in a parent study (NSCT/CT/18/01). vMCO-I is a gene therapy product based on an adeno-associated viral vector serotype 2 carrying the Multi-Characteristic Opsin gene. Participants undergo safety and efficacy assessments for up to 5 years after the study drug injection, and the study is conducted under Good Clinical Practice (GCP) and ICH guidelines.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * The subject population includes subjects who received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I), administered via intravitreal injection in a parent study. Exclusion Criteria: * Subjects who will not consent for study.